(Q37725970)

22 August 2017

1 reference

title

Evolution of endocrine adjuvant therapy for early breast cancer (English)

1 reference

22 August 2017

1

Per Eystein Lønning

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19 Suppl 1

1 reference

22 August 2017

page(s)

S19-30

1 reference

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Additive endocrine therapy for advanced breast cancer - back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Progestins in breast cancer treatment. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Current status of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Genomics in breast cancer-therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Mechanisms of resistance to aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Aromatase inhibitors: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Cloning of a novel receptor expressed in rat prostate and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

ER beta: identification and characterization of a novel human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

The evolving role of oestrogen receptor beta in clinical breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Homodimerization through coiled-coil regions enhances activity of the myotonic dystrophy protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Mechanisms of action of endocrine treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Genotype-guided tamoxifen therapy: time to pause for reflection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Human aromatase: gene resequencing and functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Zoledronic acid - a multiplicity of anti-cancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Adjuvant endocrine treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

The simplest statistical test: how to check for a difference between treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003714865

10.1517/13543781003714865

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference